Decub-Amine (whey protein concentrate/arginine/glutamine/flaxseed)
Oral Powder (Gram)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: whey protein concentrate/arginine/glutamine/flaxseed
Therapeutic class: Electrolyte Balance-Nutritional Products
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Decub-Amine
Indications
No indications are available for this drug.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Disease Modifying Agents/Exagamglogene Autotemcel
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: The interaction potential of disease modifying agents with exagamglogene autotemcel is unknown.(1)
CLINICAL EFFECTS: Disease modifying agents may interfere with exagamglogene autotemcel therapy.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Discontinue disease modifying therapies for sickle cell disease (e.g. voxelotor, crizanlizumab) at least 8 weeks prior to the start of mobilization.(1) It is recommended that patients be transfused at least 8 weeks prior to the initiation of myeloablative conditioning. At initiation of red blood cell exchange or simple transfusions, discontinue disease modifying therapies for sickle cell disease (e.g. voxelotor, crizanlizumab).(1)
DISCUSSION: There is no experience with the use of disease modifying agents with exagamglogene autotemcel infusion.(1)
Disease Modifying Agents/Lovotibeglogene Autotemcel
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: The interaction potential of disease modifying agents with lovotibeglogene autotemcel is unknown.(1)
CLINICAL EFFECTS: Disease modifying agents may interfere with lovotibeglogene autotemcel therapy.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Discontinue disease modifying therapies (e.g. voxelotor, crizanlizumab) for sickle cell disease at least 8 weeks prior to start of mobilization and conditioning.(1)
DISCUSSION: There is no experience with the use of disease modifying agents with lovotibeglogene autotemcel infusion.(1)
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Appendicitis
- Esophageal obstruction
- Gastrointestinal obstruction
- Paralytic ileus
- Pyloroduodenal obstruction
There are no severe contraindications for this drug.
- Inflammatory bowel disease
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Neuropsychiatric disorder
More Frequent
- Acute abdominal pain
- Constipation
- Cough
- Flatulence
- Headache disorder
- Nausea
Less Frequent
- Abdominal distension
- Abnormal hepatic function tests
- Back pain
- Chest pain
- Diarrhea
- Nausea
- Pain in extremities
- Vomiting
Rare or Very Rare
- Behavioral disorders
- Constipation
- Dyspepsia
- Hypertriglyceridemia
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.